Ascentage Pharma (AAPG) announced that it has received clearance by the U.S. Food and Drug Administration, FDA, and the European Medicines Agency, EMA, to conduct GLORA-4 study, a global registrational Phase III study of lisaftoclax, APG-2575, a proprietary Bcl-2 inhibitor, in combination with azacitidine, for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma to Announce 2025 Interim Results and Corporate Update
- Ascentage Pharma to Engage in Evercore China Biotech Summit
- Ascentage Pharma Completes Offshore Placement to Boost Global Operations
- Ascentage Pharma announces China NMPA approval of lisaftoclax
- Ascentage Pharma Strengthens Leadership with Key Appointments